AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth ExpectationsBenzinga • Friday
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisPRNewsWire • Friday
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • Thursday
Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?Zacks Investment Research • Thursday
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer DrugsBenzinga • Thursday
AbbVie Slides Despite Beating Second-Quarter Views, Raising GuidanceInvestors Business Daily • Thursday
AbbVie's quarterly results top estimates as newer drugs cushion Humira's slideMarket Watch • Thursday
My Dividend Stock Portfolio: New June Dividend Record - 101 Holdings With 22 BuysSeeking Alpha • Wednesday
Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription FactorGlobeNewsWire • Tuesday
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?The Motley Fool • Monday